Home Stock

Stock Research: Novo Nordisk

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Novo Nordisk

CPH:NOVO B DK0060534915
1
  • Value
    45
  • Growth
    20
  • Safety
    Safety
    32
  • Combined
    17
  • Sentiment
    1
  • 360° View
    360° View
    1
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Novo Nordisk A/S is a global healthcare company specializing in diabetes care, and the development, manufacturing, and marketing of pharmaceutical products. It operates in the diabetes and obesity care, and biopharmaceuticals industries, with products like NovoLog/NovoRapid and NovoSeven. The company markets its products in over 180 countries, with commercial units in North America and International Operations. In the last fiscal year, the company had a market cap of $300970 million, profits of $34273 million, and revenue of $40321 million, with 76302 employees.

more

ANALYSIS: With an Obermatt 360° View of 1 (better than 1% compared with alternatives), overall professional sentiment and financial characteristics for the stock Novo Nordisk are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with all four indicators below average for Novo Nordisk. The consolidated Value Rank has a low rank of 45 which means that the share price of Novo Nordisk is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 55% of alternative stocks in the same industry. The consolidated Growth Rank also has a low rank of 20, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is lower than for 20% of competitors in the same industry. The consolidated Safety Rank has a riskier rank of 32, which means that the company has a riskier financing structure than 68% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a low rank of 1, which means that professional investors are more pessimistic about the stock than for 99% of alternative investment opportunities. ...read more

more
Strongest Rank Sentiment
Weakest Rank Profit Growth
Country Denmark
Industry Pharmaceuticals
Size XX-Large
Website novonordisk.com
Index
OMX C20
Novo Nordisk stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 3-Sep-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
45 12 9 12
Growth
20 42 99 69
Safety
Safety
32 26 48 68
Sentiment
1 34 30 8
360° View
360° View
1 7 37 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
3 42 28 9
Opinions Change
12 31 52 34
Pro Holdings
n/a 87 82 74
Market Pulse
14 24 15 17
Sentiment
1 34 30 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
45 12 9 12
Growth
20 42 99 69
Safety Safety
32 26 48 68
Combined
17 7 54 48
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
37 7 7 13
Price vs. Earnings (P/E)
29 14 11 17
Price vs. Book (P/B)
21 1 1 1
Dividend Yield
88 68 61 61
Value
45 12 9 12
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
19 89 79 61
Profit Growth
94 65 84 54
Capital Growth
19 16 82 29
Stock Returns
18 12 94 92
Growth
20 42 99 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for more than 8,000 stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
30 25 52 65
Refinancing
4 6 11 12
Liquidity
85 86 85 85
Safety Safety
32 26 48 68

Similar Stocks

Discover high‑ranked alternatives to Novo Nordisk and broaden your portfolio horizons.

Fresenius

GER:FRE
Country: Germany
Industry: Health Care Services
Size: X-Large
Full Stock Analysis

Henkel

GER:HEN3
Country: Germany
Industry: Household Products
Size: X-Large
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Strabag

VIE:STR
Country: Austria
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews